Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).

Reviewer: Christopher Dolinsky, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 14 de mayo del 2005

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015